$153.43
2.75% yesterday
Nasdaq, Nov 05, 10:00 pm CET
ISIN
US09062X1037
Symbol
BIIB

Biogen Stock price

$153.43
-0.62 0.40% 1M
+31.63 25.97% 6M
+0.51 0.33% YTD
-23.50 13.28% 1Y
-131.19 46.09% 3Y
-175.47 53.35% 5Y
-116.48 43.16% 10Y
+114.89 298.12% 20Y
Nasdaq, Closing price Wed, Nov 05 2025
+4.10 2.75%
ISIN
US09062X1037
Symbol
BIIB
Industry

New AI Insights on Biogen Insights AI Insights on Biogen

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$21.9b
Enterprise Value
$24.2b
Net debt
$2.3b
Cash
$4.0b
Shares outstanding
146.7m
Valuation (TTM | estimate)
P/E
13.7 | 9.3
P/S
2.2 | 2.2
EV/Sales
2.4 | 2.5
EV/FCF
10.7
P/B
1.2
Financial Health
Equity Ratio
59.6%
Return on Equity
9.8%
ROCE
11.1%
ROIC
10.3%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$10.1b | $9.9b
EBITDA
$3.3b | $3.3b
EBIT
$2.9b | $3.0b
Net Income
$1.6b | $2.4b
Free Cash Flow
$2.3b
Growth (TTM | estimate)
Revenue
4.8% | 2.0%
EBITDA
16.5% | 9.1%
EBIT
15.2% | 13.4%
Net Income
-0.4% | 44.7%
Free Cash Flow
27.9%
Margin (TTM | estimate)
Gross
75.2%
EBITDA
33.1% | 33.6%
EBIT
28.5%
Net
16.0% | 23.9%
Free Cash Flow
22.5%
More
EPS
$10.9
FCF per Share
$15.4
Short interest
4.6%
Employees
8k
Rev per Employee
$1.3m
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

42 Analysts have issued a Biogen forecast:

21x Buy
50%
21x Hold
50%

Analyst Opinions

42 Analysts have issued a Biogen forecast:

Buy
50%
Hold
50%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
10,066 10,066
5% 5%
100%
- Direct Costs 2,492 2,492
6% 6%
25%
7,574 7,574
4% 4%
75%
- Selling and Administrative Expenses 2,426 2,426
5% 5%
24%
- Research and Development Expense 1,780 1,780
14% 14%
18%
3,335 3,335
16% 16%
33%
- Depreciation and Amortization 466 466
25% 25%
5%
EBIT (Operating Income) EBIT 2,869 2,869
15% 15%
29%
Net Profit 1,609 1,609
0% 0%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
GlobeNewsWire
2 days ago
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology's (ASN) annual meeting, taking place November 5-9 in Houston, Texas. Felzartamab, an investigational anti-CD38 monoclonal antibody, is currently being evaluated in three pivotal Phase 3 s...
Neutral
Seeking Alpha
6 days ago
Biogen Inc. ( BIIB ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Alisha Alaimo - President & Head of North America Robin Kramer - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities,...
Negative
WSJ
6 days ago
Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer's drug and rare-disease treatments.
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,605
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today